11-17 March 2017
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
Early treatment with disease modifying drugs
A trial of Rebif in people with clinically isolated syndrome (CIS) found that the proportion of people who had been diagnosed with definite MS was lower in the taking the drug from the start of the study than in the group that had originally been on a placebo for the first two years.
Source: Neurology Reviews
MS Trust link: MS Decisions - a guide to the disease modifying drugs
Neurological services declining
A Neurological Alliance survey has found a decline in neurological services since a previous study in 2014. There were increases in the proportion of people seeking a diagnosis who saw their GP five or more times before seeing a neurologist; decrease in the proportion who felt involved in making choices; and a drop in people who feel that health professionals work well together
Source: Neurological Alliance
MS Trust link: People with neurological conditions ‘being failed’ by services - MS Trust news item
Caroline Wyatt and stem cell therapy
Jeremy Vine's show on Radio 2 included an interview with the BBC reporter Caroline Wyatt, who recently had stem cell therapy for her MS. She describes her diagnosis, her treatment the recovery process. Also on the BBC, the World Service has broadcast an investigation into clinics that charge people with long-term conditions for experimental stem cell approaches
MS Trust link: Stem cell therapy
Daclizumab (Zinbryta) approved in England and Wales
The National Institute for Health and Care Excellence (NICE) 705 has approved a new disease modifying drug for relapsing remitting MS in England and Wales.
Source: Pharma Times
MS Trust link: Zinbryta (daclizumab) approved for use by the NHS in England and Wales - MS Trust news item
Delayed acceptance of NICE approved drugs
From April, NHS England will be able to ask the National Institute for Health and Care Excellence (NICE) to delay approval of new drugs if the cost is expected to be more than £20m in any of the first three years of implementation.